The third and final portion of Bryant’s exclusive video interview with PharmTech ® deals with the processes known as human-in ...

Our data show that global pharma M&A is becoming more selective and strategically targeted. While North America remains the ...

Next-generation biologics, such as bispecifics, fusion proteins, and multi-specifics, have multiple functionalities that ...

Digital GMP expectations are increasing, driven by Annex 11 and Annex 22, necessitating robust lifecycle management, data ...

Felix Gonzalez, FounderNest, offers a data-driven view of where pharma consolidation is occurring, where capital is being deployed, and how regional M&A strategies differ.

The field of cancer treatment saw a variety of advancements in 2025, from new dedicated centers to approved treatments to ...

In an expansion of his written three-part series for PharmTech, Jason Bryant of ArisGlobal explains the interplay between autonomy and accountability that is essential for AI agents assisting the ...

In an expansion of his written three-part series for PharmTech, Jason Bryant of ArisGlobal explains the interplay between ...

Autonomy is not a binary option, Bryant said in the first part of this video interview with PharmTech ®, and can work in ...

The year 2025 was defined by escalating global trade tensions that fundamentally reshaped the pharmaceutical supply chain, ...

From a global regulatory perspective, Cytokinetics is expanding its footprint rapidly. The drug received approval in China on ...

The top 10 PharmTech videos of the year cover advanced therapies, high-concentration biologics, major mergers and ...